Powered by HealthTechMovers.com
We added 7 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
Karuna Therapeutics, KRTX
Summary: Karuna Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical needs. The company's product candidate consists of KarXT, for the treatment of acute psychosis in patients with schizophrenia, which are in clinical stage. Karuna Therapeutics Inc. is based in Boston, Massachusetts.
- Last Price: $273.71
- Price Change: -$3.71, -1.34%
- Yearly Gain: 164.56%
- Market Cap: $9.27B
- P/E Ratio: -40.859
Here are 3rd party ratings for KRTX:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 29% (73 out of 252)
What is the sentiment on the street regarding Karuna Therapeutics ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Neutral
If you are interested in KRTX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on KRTX before you decide to make any investment.
Click here for chart >>
NeoGenomics, NEO
Summary: NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States.
- Last Price: $12.91
- Price Change: $0.29, 2.3%
- Yearly Gain: -70.10%
- Market Cap: $1.57B
- P/E Ratio: -10.609
Here are 3rd party ratings for NEO:
- TipRanks.com: Moderate Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 29% (73 out of 252)
What is the sentiment on the street regarding NeoGenomics ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus: Bullish
- Media Buzz: High
- Insider Signal: Positive
- Investor Sentiment: Positive
- Hedge Fund signal: Positive
If you are interested in NEO or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on NEO before you decide to make any investment.
Click here for chart >>
Catalyst Pharma, CPRX
Summary: Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, like Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy and Tourette syndrome. Catalyst in-licensed rights to Firdapse (for treating LEMS) from BioMarin Pharmaceutical Inc. for its development and commercialization in the U.S. Firdapse is currently approved in the European Union and in the U.S. for treating of LEMS in adults. The company also plans to file a supplemental new drug application for Firdapse to treat pediatric patients with LEMS.'The company is also strengthening the commercial portfolio of Firdapse. It has already received multiple patents that cover the treatment of all amifampridine metabolizer types within the LEMS patient population.'Apart from Firdapse, the company is working on a generic version of Lundbeck's Sabril, CPP-109, for the treatment of infantile spasms and complex partial seizures.
- Last Price: $14.23
- Price Change: $0.33, 2.37%
- Yearly Gain: 143.43%
- Market Cap: $1.43B
- P/E Ratio: 27.772
Here are 3rd party ratings for CPRX:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 33% (78 out of 252)
What is the sentiment on the street regarding Catalyst Pharma ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: High
- Insider Signal: Neutral
- Investor Sentiment: Very Positive
- Hedge Fund signal: Neutral
If you are interested in CPRX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on CPRX before you decide to make any investment.
Click here for chart >>
Altimmune, ALT
Summary: Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly known as Pharmathene Inc., is based in Gaithersburg, United States.
- Last Price: $17.54
- Price Change: $0.18, 1.04%
- Yearly Gain: 49.01%
- Market Cap: $750.29M
- P/E Ratio: -7.722
Here are 3rd party ratings for ALT:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 33% (78 out of 252)
What is the sentiment on the street regarding Altimmune ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Positive
- Hedge Fund signal: Neutral
If you are interested in ALT or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on ALT before you decide to make any investment.
Click here for chart >>
Caribou Biosciences, CRBU
Summary: Caribou Biosciences Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company. It involved in developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors. Caribou Biosciences Inc. is based in BERKELEY, Calif.
- Last Price: $10.02
- Price Change: $0.11, 1.11%
- Yearly Gain: -62.58%
- Market Cap: $601.59M
- P/E Ratio: -7.024
Here are 3rd party ratings for CRBU:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Sell, Top 29% (73 out of 252)
What is the sentiment on the street regarding Caribou Biosciences ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Neutral
If you are interested in CRBU or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on CRBU before you decide to make any investment.
Click here for chart >>
CymaBay Therapeutics, CBAY
Summary: CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California.
- Last Price: $4.05
- Price Change: $0.04, 1%
- Yearly Gain: 11.08%
- Market Cap: $339.56M
- P/E Ratio: -3.091
Here are 3rd party ratings for CBAY:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 37% (94 out of 252)
What is the sentiment on the street regarding CymaBay Therapeutics ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Neutral
If you are interested in CBAY or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on CBAY before you decide to make any investment.
Click here for chart >>
Apyx Medical, APYX
Summary: Apyx Medical Corporation is an energy technology company. It provides products in the cosmetic and surgical markets. The company's Helium Plasma Technology is marketed and sold as Renuvion(R) in the cosmetic surgery market and J-Plasma(R) in the hospital surgical market. Apyx Medical Corporation, formerly known as Bovie Medical Corporation, is based in FL, United States.
- Last Price: $7.47
- Price Change: -$0.78, -9.45%
- Yearly Gain: -18.64%
- Market Cap: $284.24M
- P/E Ratio: -16.132
Here are 3rd party ratings for APYX:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Bottom 42% (145 out of 252)
What is the sentiment on the street regarding Apyx Medical ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Positive
- Hedge Fund signal: Neutral
If you are interested in APYX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on APYX before you decide to make any investment.
Click here for chart >>
Thanks for reading!